Pharmacogenomic investigation of SETMAR fusion gene on near-Haploid Lymphoblastoid Leukemia (HAP1) cell line

Abstract

Given the lack of studied knowledge on the effects of SETMAR expression on drug sensitivity, we aimed to investigate various FDA-approved drugs impacting the viability of various genetically modified near-haploid human cell lines (HAP1) by applying high-content screening on the FDA-approved drug libraries in order to choose hits of active compounds for further analysis. HAP1 cells were treated with the hits (drugs) to evaluate how these drugs might influence cellular processes if we manipulated SETMAR expression levels in these cell lines.